Page 196 - Binder2

This local, non-inflammatory exposure is what enables:

• Immune training rather than immune suppression
• Regulatory T cell induction instead of effector T
cell priming
• Durable immune silence, not just temporary
therapeutic effect

And because the therapy never needs to enter the
bloodstream, the risk of systemic immunogenicity—anti-
drug antibodies, infusion reactions, chronic immune
exhaustion—is significantly reduced.

This isn’t drug delivery.
It’s immune communication—engineered from the
capsule backward.

Designing for Persistence, Not Potency

It’s tempting to view oral delivery through the lens of
convenience: easier administration, better compliance,
lower cost. And all of that is true.

But the deeper story is immunologic alignment.

When you design biologics that survive digestion, you’re
not just ensuring they reach the gut.
You’re ensuring they reach the immune system in a form
it understands.

That’s not convenience.
That’s strategy.

194